Vasogen ends Phase III arterial disease drug trial early on recommendation

TORONTO (CP) - Vasogen Inc. said Tuesday it has brought an early close to a Phase III trial of its Celacade drug for the treatment of chronic inflammation associated with cardiovascular disease....More